Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:AVDL NASDAQ:RVNC NASDAQ:SDGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.36-0.3%$4.84$3.21▼$7.18$1.53B0.684.55 million shs2.37 million shsAVDLAvadel Pharmaceuticals$14.76+1.0%$11.44$6.38▼$16.66$1.43B1.471.34 million shs1.65 million shsRVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.78 million shsN/ASDGRSchrodinger$19.51-1.3%$20.53$16.60▼$28.47$1.44B1.671.41 million shs703,990 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%+4.09%+50.00%+70.97%+3.41%AVDLAvadel Pharmaceuticals0.00%-3.15%+40.44%+61.66%-0.67%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%-44.53%SDGRSchrodinger0.00%-3.99%-4.03%-9.80%-4.64%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.0824 of 5 stars3.52.00.04.41.92.50.6AVDLAvadel Pharmaceuticals2.8607 of 5 stars3.63.00.00.02.91.70.6RVNCRevance Therapeutics1.5666 of 5 stars2.00.00.04.70.01.70.6SDGRSchrodinger3.0311 of 5 stars3.33.00.00.02.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$11.5080.82% UpsideAVDLAvadel Pharmaceuticals 3.14Buy$19.6733.24% UpsideRVNCRevance Therapeutics 2.00Hold$4.2315.98% UpsideSDGRSchrodinger 2.67Moderate Buy$27.8342.66% UpsideCurrent Analyst Ratings BreakdownLatest RVNC, SDGR, AVDL, and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $20.008/18/2025SDGRSchrodingerMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$28.00 ➝ $19.008/15/2025SDGRSchrodingerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$35.00 ➝ $20.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.008/14/2025SDGRSchrodingerBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$25.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/8/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $24.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$386.15M3.97N/AN/A$0.58 per share10.97AVDLAvadel Pharmaceuticals$169.12M8.47N/AN/A$0.93 per share15.87RVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11SDGRSchrodinger$207.54M6.92N/AN/A$4.66 per share4.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A20.52N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A246.00N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%N/ASDGRSchrodinger-$187.12M-$2.48N/AN/AN/A-76.22%-45.70%-24.81%11/11/2025 (Estimated)Latest RVNC, SDGR, AVDL, and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025SDGRSchrodinger-$0.83-$0.59+$0.24-$0.59$52.03 million$54.76 million8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ASDGRSchrodingerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03AVDLAvadel PharmaceuticalsN/A2.792.38RVNCRevance TherapeuticsN/A4.123.05SDGRSchrodingerN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AVDLAvadel Pharmaceuticals69.19%RVNCRevance Therapeutics97.70%SDGRSchrodinger79.05%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%AVDLAvadel Pharmaceuticals5.20%RVNCRevance Therapeutics5.10%SDGRSchrodinger21.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableRVNCRevance Therapeutics500104.39 million99.07 millionOptionableSDGRSchrodinger79073.61 million58.15 millionOptionableRVNC, SDGR, AVDL, and ARDX HeadlinesRecent News About These CompaniesTema Etfs LLC Sells 18,331 Shares of Schrodinger, Inc. $SDGR2 hours ago | marketbeat.comNuveen LLC Makes New $2.87 Million Investment in Schrodinger, Inc. $SDGR5 hours ago | marketbeat.comAlphaQuest LLC Trims Holdings in Schrodinger, Inc. $SDGRAugust 29 at 4:57 AM | marketbeat.comDeutsche Bank AG Sells 188,717 Shares of Schrodinger, Inc. $SDGRAugust 27, 2025 | marketbeat.comAmerican Century Companies Inc. Invests $19.79 Million in Schrodinger, Inc. $SDGRAugust 26, 2025 | marketbeat.comSchrodinger, Inc. $SDGR Shares Sold by Vanguard Group Inc.August 24, 2025 | marketbeat.comSchrödinger: A Complex Story With Many Moving PartsAugust 21, 2025 | seekingalpha.comPublic Sector Pension Investment Board Raises Stake in Schrodinger, Inc. $SDGRAugust 21, 2025 | marketbeat.comCetera Investment Advisers Takes Position in Schrodinger, Inc. $SDGRAugust 21, 2025 | marketbeat.comMorgan Stanley Cuts Schrodinger (NASDAQ:SDGR) Price Target to $19.00August 20, 2025 | marketbeat.comMorgan Stanley Issues Pessimistic Forecast for Schrodinger (NASDAQ:SDGR) Stock PriceAugust 20, 2025 | americanbankingnews.comWhat 4 Analyst Ratings Have To Say About SchrodingerAugust 18, 2025 | benzinga.comTocqueville Asset Management L.P. Sells 23,590 Shares of Schrodinger, Inc. (NASDAQ:SDGR)August 18, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Shares Gap Down - Should You Sell?August 17, 2025 | marketbeat.comSchrodinger (NASDAQ:SDGR) Upgraded to Strong-Buy at BarclaysAugust 17, 2025 | marketbeat.comTejara Capital Ltd Has $2.65 Million Holdings in Schrodinger, Inc. (NASDAQ:SDGR)August 17, 2025 | marketbeat.comSchrodinger (SDGR) Gets a Buy from BarclaysAugust 16, 2025 | theglobeandmail.comCraig-Hallum Sticks to Its Buy Rating for Schrodinger (SDGR)August 16, 2025 | theglobeandmail.comSchrodinger (NASDAQ:SDGR) Sets New 12-Month Low - Here's What HappenedAugust 16, 2025 | marketbeat.comSchrodinger downgraded at Citi after clinical program exitAugust 16, 2025 | msn.comCitigroup Downgrades Schrödinger (SDGR)August 16, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVNC, SDGR, AVDL, and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$6.36 -0.02 (-0.31%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.34 -0.02 (-0.33%) As of 08/29/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDL$14.76 +0.14 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.05 +0.29 (+1.99%) As of 08/29/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Revance Therapeutics NASDAQ:RVNCRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.Schrodinger NASDAQ:SDGR$19.51 -0.25 (-1.27%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$19.52 +0.00 (+0.03%) As of 08/29/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
